Expert on Demand in
Triple Negative Breast Cancer (TNBC)
The Expert on Demand programme at MSD provides an exciting opportunity for you and your MDT to connect with Key Opinion Leaders in TNBC at a time that works for you.
How to sign up?
- Choose your module
- Complete the form below to express your interest
- You will be contacted by your local MSD representative to arrange a suitable time and date
Read more about the available modules in TNBC below:
Advancing treatment outcomes
in triple-negative breast cancer (TNBC)
This module provides an overview of the KEYNOTE-522 study.
We explore who the eligible patient is for this treatment
regimen and look at the updated results from the 75-month follow-up.
Our expert speakers will also be able to share best practice
on managing this regimen in your hospital.
Learning Objectives – To enhance knowledge around the…
-
Factors to consider when initiating treatment
of early-stage TNBC -
Use of pembrolizumab as neoadjuvant/adjuvant treatment
in TNBC (using key data from KEYNOTE-522) -
Impact of neoadjuvant/adjuvant pembrolizumab on the
adverse event profile in TNBC -
How to optimise adverse event management and patient
outcomes in early-stage TNBC
Speakers
Dr Mukesh Mukesh
East Suffolk and North Essex NHS Trust
Biography
Dr Mukesh graduated from medical school in India in 2003 with distinction and undertook specialist training in Clinical Oncology at Cambridge. He completed MSc in Oncology from the Institute of Cancer Research, London with distinction & Fellowship of the Royal College of Radiologists in 2010. He completed Doctorate of Medicine (MD) with Ralph Noble prize from the University of Cambridge in 2018 for breast radiotherapy research.
He is a consultant Clinical Oncologist at East Suffolk & North Essex NHS Trust specialising in breast cancer and melanoma. His clinical interest includes clinical trials, immunotherapy & personalised cancer therapy.
Dr Melissa Phillips
Barts Cancer Institute, London
Biography
Dr Phillips is a Consultant Medical Oncologist at St Bartholomew’s Hospital, London, specialising in breast cancer. She studied medicine at King’s College London and subsequently completed her general medical training at Imperial College Healthcare NHS Trust and her specialist training in medical oncology at Barts Health NHS Trust. In 2010 she undertook a PhD in Molecular Oncology, investigating the role of the tumour microenvironment in drug resistance. Her current role focuses on the management of breast cancer. She is a Principle and Co-investigator on a variety of clinical trials in early and metastatic breast cancer. She has authored or co-authored a number of publications and has presented at local and national conferences. She has particular interest in the management of early breast cancer.
Enhancing treatment and decision-making for triple-negative
breast cancer (TNBC) patients
This module focuses on the impact of the KEYNOTE-522 regimen
on surgical outcomes in TNBC. Our expert speakers will provide an overview of the KEYNOTE-522 data and the practical
implications to consider before, during and after surgery.
Learning Objectives –
-
Discuss the evolving surgical and medical treatment landscape for
early-stage TNBC -
Understand the unmet need for neoadjuvant systemic anti-cancer
therapy beyond surgical outcomes -
Discuss the data, rationale and patient eligibility for immunotherapy as neoadjuvant and adjuvant treatment in early-stage TNBC and
related AE management -
Build collaboration and communication in the surgical
and oncological treatment of TNBC
Speakers
Mr Henry Cain
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
Biography
Mr Cain is an established consultant Oncoplastic Breast Surgeon with specialist research interest in the molecular basis of breast cancer and the use of neoadjuvant chemotherapy. He provides specialist expertise and services in breast and reconstructive surgery for patients with breast cancer and is the surgical lead for the teenage and young adult breast cancer service. Mr Cain qualified in 2001 from Leicester, completed his surgical training in the North of England, and following the award of MD in breast cancer signalling pathways and higher surgical training he spent a year as the Oncoplastic Fellow at the Canniesburn Unit in Glasgow. In 2013, he was appointed a Consultant Oncoplastic surgeon at the Royal Victoria Infirmary Newcastle upon Tyne.
Mr Cain participates in numerous research activities whilst maintaining a commitment to teaching advanced oncoplastic breast surgery. He has delivered various clinical trials including LORIS, ATNEC, HORIZON and the SMALL trial and is the chief investigator of the multi centre randomised control trial PRE-DX. He is also the surgical lead for the national NOSTRA study. His area of interest is the development of clinical strategies for the delivery of new breast cancer therapies.
Professor Stuart McIntosh
Belfast City Hospital
Biography
Professor McIntosh is a Clinical Reader in Surgical Oncology at Queen’s University in Belfast, and an honorary consultant breast surgeon at Belfast City Hospital. He graduated from Edinburgh University in 1993, completing general surgical training in the North-East of Scotland, moving to Belfast in 2009, and to an academic position in 2015. He has been a consultant oncoplastic and reconstructive breast surgeon since 2005, with extensive clinical experience in the management of both breast cancer and benign breast conditions. He is an experienced breast cancer clinical trialist, having contributed to numerous trials in early breast cancer, with a particular emphasis on neoadjuvant, peri-surgical and treatment de-escalation studies. He is the Chief Investigator for the UK HTA funded SMALL trial, a national phase III multicentre study comparing standard surgery with vacuum-assisted excision for the treatment of small screen-detected breast cancers.His translational research interests lie in the area of the DNA damage immune response in breast cancer. He is Chair of the UK National Cancer Research Institute Breast Research Group and a member of the NCRI Strategic Advisory Group, and he has an excellent overview of the portfolio of clinical and translational breast cancer research in the UK. In his role as the Royal College of Surgeons Breast Surgical Specialty Lead, he is responsible for supporting the development and delivery of breast cancer trials nationally, with a specific emphasis on surgical studies. In addition, he is also Clinical Director for the Northern Ireland Cancer Trials Network, responsible for overseeing delivery of cancer clinical research across the five cancer hospitals in Northern Ireland.
KEYTRUDA (pembrolizumab) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.1
Please refer to the SmPC for further information before making any prescribing decisions.
Reference
- KEYTRUDA Summary of Product Characteristics
Supporting Documentation
Prescribing Information [External link]
To register your interest in Expert on Demand please complete the form below:
